Geron (NASDAQ:GERN) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Geron (NASDAQ:GERN) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05, Briefing.com reports. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The firm had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same period last year, the firm posted ($0.08) earnings per share. Geron’s revenue for the quarter was up 17138.4% compared to the same quarter last year.

Geron Stock Down 0.9 %

NASDAQ:GERN traded down $0.04 during mid-day trading on Friday, hitting $4.25. 12,139,002 shares of the company’s stock traded hands, compared to its average volume of 7,352,321. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. The company has a market capitalization of $2.56 billion, a P/E ratio of -11.81 and a beta of 0.52. The company has a fifty day moving average of $4.31 and a 200 day moving average of $4.30. Geron has a twelve month low of $1.64 and a twelve month high of $5.34.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GERN shares. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Geron in a report on Friday, August 9th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Geron in a research note on Thursday, August 8th. StockNews.com upgraded shares of Geron to a “sell” rating in a report on Monday, August 5th. HC Wainwright initiated coverage on shares of Geron in a report on Tuesday. They set a “buy” rating and a $8.00 price objective for the company. Finally, Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.